邁克生物(300463.SZ)2019年度淨利潤升18.06%至5.25億元 擬10派1.89元
格隆匯4月16日丨邁克生物(300463.SZ)發佈2019年年度報告，實現營業收入32.23億元，同比增長20.02%；歸屬上市公司股東淨利潤5.25億元，同比增長18.06%；歸屬於上市公司股東的扣除非經常性損益的淨利潤5.19億元，同比增長18.97%；基本每股收益0.9494元，擬每10股派發現金紅利1.89元(含税)。經營活動產生的現金流量淨額4.60億元，同比增長136.98%。
公司主要從事體外診斷產品研發、生產、銷售和服務。公司自成立之初始終專注於體外診斷產業，堅持以自主研發為主，以客户需求為導向、以滿足臨牀應用為己任，以專業化產品和優質的服務為醫學實驗室提供整體解決方案。歷經二十餘年發展，公司已具備研發製造體外診斷設備、試劑、校準品和質控品的系統化專業能力，已完成從生物原材料、醫學實驗室產品到專業化服務的全產業鏈發展佈局。
目前，公司自主產品涵蓋生化、免疫、血液、分子診斷、快速檢測、病理、原材料等多個技術平台，已成為國內體外診斷生產企業中產品品種最為豐富的企業之一。公司將繼續圍繞技術創新，推動自主產品從產品系列化至產品系統化、自動化集成的發展目標。現階段，公司免疫產品已實現流水線集成，是國內為數不多的可提供實驗室自動化產品的體外診斷生產企業。
公司研發成果進入快速轉換期，報告期新增產品註冊證91項，其中除了直接化學發光法下的全自動化學發光分析儀配套試劑持續豐富至29項外，全自動生化分析儀C800成功上市，快檢類推出血糖檢測產品、甲型流感病毒抗原檢測試劑，公司分子平台第一款產品乙型肝炎病毒核酸測定試劑盒(熒光PCR 法)也成功獲證。2019年末公司免疫產品流水線聯機，同時通過與日立進行戰略合作，推出生化免疫流水線提供實驗室自動化解決方案，公司研發和產品競爭力進一步提升。
報告期內，公司自主產品收入增速23.21%，代理產品收入增速為18.21%，當期淨利潤75%來源於自主產品貢獻，經營目標達成較好。公司實現自主產品營收12.16億，三大產品平台均實現預期增長目標。生化產品市場份額不斷擴大，生化試劑銷售同比增長17.69%；隨着i 3000全自動化學發光免疫分析儀的裝機運行，產品性能尤其是傳染病、甲功等項目上獲得了較高的臨牀評價，存量市場單機試劑產出快速提升，化學發光試劑銷售收入同比增長29.48%；血球為主的臨檢板塊日漸成熟，F580/F560裝機量增長迅速，血球試劑銷售收入同比增長78.51%。公司將進一步加強邁克品牌的市場推廣力度，實現邁克品牌美譽度和影響力向產品市場覆蓋和銷售業績的轉化。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
